Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.

Fiche publication

Date publication

janvier 2026

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain , Pr PETIT Thierry

Tous les auteurs :
Lynce F, Valenza C, Niman SM, Bertucci F, Kai M, Ryan S, Troll E, Layman RM, Fanucci KA, Giordano A, Nasrazadani A, Nakhlis F, Bellon J, Warren L, Block C, Schumer S, Lucci A, Krishnamurthy S, Trapani D, Lerebours F, Dalenc F, Levy C, Petit T, Leheurteur M, Bachelot T, Tredan O, Ribeiro JM, Pistilli B, Zagami P, Ladoire S, Lopez Almeida L, Zemmour C, Carey LA, Tolaney SM, Valero V, ,Curigliano G, Regan MM, Goncalves A, Woodward WA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41558201

Résumé

The efficacy of neoadjuvant chemoimmunotherapy in patients with non-metastatic triple-negative inflammatory breast cancer (TN-IBC) remains unclear, as patients with IBC have been poorly represented in pivotal clinical trials.